inhibit ability immune cells autodestruct outlived usefulness resulting higher concentrations proinflammatory signals intestines ibd patients hakonarson hopes team discovery lead better therapies designing small molecules bind receptor reducing destructive new therapies alleviate problems plaguing current treatments ibd injections antibodies target clear excess tnf antibody approach successful increases risk severe allergic reactions possibility patient immune system sensitized destroying antibodies making long term treatment effective inert tablet designed block receptor targeting tnf circumvent issues alleviate inflammation ibd 10 years studies identify potential pathways new therapies says judy cho director yale university school medicine inflammatory bowel disease center not involved research treatment helpful